Cape Town - Local tuberculosis experts are optimistic that a novel TB antibiotic, which is being tested on multidrug-resistant TB sufferers in a Cape Town hospital, could revolutionise treatment of the killer disease.
Delamanid, which was tested on about 70 patients in the Brooklyn Chest Hospital, showed impressive results within the first two months of treatment.
It was provisionally approved for marketing by the European Medicines Agency following its positive results in more than 500 MDR TB patients on which it was tested around the world.
It has not yet been registered by South Africa’s regulatory body, the Medicines Control Council.
Used in combination with other anti-TB medicines, Delamanid was the second new TB drug to receive a positive opinion from the US Food and Drug Administration and the European Medicines Agency after Bedaquiline in several decades.